140 related articles for article (PubMed ID: 32729292)
1. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
Samal S; Patnaik A; Sahu F; Purkait S
Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
[TBL] [Abstract][Full Text] [Related]
2. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of Zeste Homolog 2 (EZH2) in Malignant Progression of Gallbladder Carcinoma.
Behera G; Mitra S; Mishra TS; Purkait S
J Gastrointest Cancer; 2021 Sep; 52(3):1029-1034. PubMed ID: 33051796
[TBL] [Abstract][Full Text] [Related]
4. The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.
Jung M; Kim SI; Lim KY; Bae J; Park CK; Choi SH; Park SH; Won JK
Hum Pathol; 2021 Sep; 115():96-103. PubMed ID: 34186055
[TBL] [Abstract][Full Text] [Related]
5. Expression of DNA methyltransferases 1 and 3B correlates with EZH2 and this 3-marker epigenetic signature predicts outcome in glioblastomas.
Purkait S; Sharma V; Kumar A; Pathak P; Mallick S; Jha P; Sharma MC; Suri V; Julka PK; Suri A; Sharma BS; Sarkar C
Exp Mol Pathol; 2016 Apr; 100(2):312-20. PubMed ID: 26892683
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
Carvalho S; Freitas M; Antunes L; Monteiro-Reis S; Vieira-Coimbra M; Tavares A; Paulino S; Videira JF; Jerónimo C; Henrique R
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2127-2137. PubMed ID: 30105513
[TBL] [Abstract][Full Text] [Related]
7. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.
Liu J; Liang L; Huang S; Nong L; Li D; Zhang B; Li T
Hum Pathol; 2019 Jan; 83():166-176. PubMed ID: 30218753
[TBL] [Abstract][Full Text] [Related]
8. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
[TBL] [Abstract][Full Text] [Related]
9. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion.
Yi X; Guo J; Guo J; Sun S; Yang P; Wang J; Li Y; Xie L; Cai J; Wang Z
Sci Rep; 2017 Jun; 7(1):3568. PubMed ID: 28620234
[TBL] [Abstract][Full Text] [Related]
10. Differential Expression of EZH2 and H3K27me3 in Oral Verrucous Carcinoma and Oral Verrucous Hyperplasia.
Sihavong P; Kitkumthorn N; Srimaneekarn N; Bumalee D; Lapthanasupkul P
Head Neck Pathol; 2021 Jun; 15(2):408-415. PubMed ID: 32720035
[TBL] [Abstract][Full Text] [Related]
11. Anxiety is associated with higher levels of global DNA methylation and altered expression of epigenetic and interleukin-6 genes.
Murphy TM; O'Donovan A; Mullins N; O'Farrelly C; McCann A; Malone K
Psychiatr Genet; 2015 Apr; 25(2):71-8. PubMed ID: 25350786
[TBL] [Abstract][Full Text] [Related]
12. Expression of EZH2 and H3K27me3 predicts tumor biology of urothelial carcinoma.
Mohamedali R; Mitra S; Mandal S; Nayak P; Adhya AK; Purkait S
Indian J Pathol Microbiol; 2023; 66(3):488-494. PubMed ID: 37530328
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim‑3 and galectin‑9, in cervical cancer.
Zhang L; Tian S; Pei M; Zhao M; Wang L; Jiang Y; Yang T; Zhao J; Song L; Yang X
Oncol Rep; 2019 Dec; 42(6):2655-2669. PubMed ID: 31661141
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 is a negative prognostic biomarker and correlated with immune infiltrates in meningioma.
Zeng J; Sun L; Huang J; Yang X; Hu W
Front Neurosci; 2022; 16():1076530. PubMed ID: 36532284
[TBL] [Abstract][Full Text] [Related]
15. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
17. Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis.
Cello G; Patel RV; McMahon JT; Santagata S; Bi WL
Acta Neuropathol Commun; 2023 Jul; 11(1):122. PubMed ID: 37491289
[TBL] [Abstract][Full Text] [Related]
18. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
He LJ; Cai MY; Xu GL; Li JJ; Weng ZJ; Xu DZ; Luo GY; Zhu SL; Xie D
Asian Pac J Cancer Prev; 2012; 13(7):3173-8. PubMed ID: 22994729
[TBL] [Abstract][Full Text] [Related]
20. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
Bae WK; Yoo KH; Lee JS; Kim Y; Chung IJ; Park MH; Yoon JH; Furth PA; Hennighausen L
Mol Carcinog; 2015 Oct; 54(10):1172-80. PubMed ID: 25043748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
